Medical Speciality Hub

In-depth medical learning materials and relevant resources by areas of interest.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Cardiology

Assorted resources on conditions connected to Cardiology.

Dermatology

Latest information on diseases in Dermatology.

Endocrinology

A detailed look at conditions connected to Endocrinology.

Gastroenterology and Hepatology

In-depth material on Gastroenterology and Hepatology.

Haematology

Assorted resources on conditions connected to Haematology.

Immunology

Immunology, the immune system and immune-mediated diseases.

Infectious Diseases

A detailed look at conditions connected to Infectious Diseases.

Nephrology

Assorted resources on conditions related to Nephrology.

Neurology (CNS) and Pain

Learning materials and guidelines on Neurology (CNS) and Pain.

Oncology

A detailed look at conditions connected to Oncology.

Ophthalmology

Assorted resources on conditions connected to Ophthalmology.

Respiratory

In-depth material on Respiratory conditions.

Rheumatology

Latest information on diseases in Rheumatology.

Urology

Learning materials and guidelines on Urology.

Latest news

Industry news

Graybug Vision to change its name to CalciMedica and merge with CalciMedica Inc.Inc

Graybug Vision, Inc.announced that it has changed its name to CalciMedica, Inc. which will become effective at 4:02 pm ET.

1 mins

Drug news

MHRA(UK) approves Vyvgart as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis who are AChR antibody positive.- argenx.

argenx a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Vyvgart (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult patients with gMG who are AChR antibody positive.

1 min

Drug news

FDA approves expanded indication for Illuccix to include patient selection for PSMA-directed radioligand therapy for prostate cancer.- Telix Pharma

Telix Pharmaceuticals announces that the FDA has approved a supplementary New Drug Application (sNDA) for Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) to enable its use for the selection of patients with metastatic prostate cancer, for whom 177Lu 177 PSMA-directed therapy is indicated.

1 min

See all news

You may be interested in...

Learning Zone Homepage

Alopecia areata Learning Zone

Unmet needs in alopecia areata, with a focus on the burden of disease, psychosocial impact on patients, developing management plans and potential emerging treatments.

Learning Zone Homepage

Weight control in type 2 diabetes

Explore the comorbidity risk of type 2 diabetes and obesity

Other insights

Empty shelves: drug shortages in the UK

Issues with shortages and supply of cold and flu drugs, antibiotics and basic medicines in the UK